Hyaluronan metabolism in remodeling extracellular matrix: Probes for imaging and therapy of breast cancer

Integrative Biology

Volumn 3, Issue 4, 2011, Pages 304-315

  Veiseh, M ^a   Turley, E A ^b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BUTYRIC ACID; CELL PROTEIN; CELL RECEPTOR; CHONDROITIN SULFATE; CISPLATIN; DOXORUBICIN; FERRIC OXIDE; FLUOROURACIL; GADOLINIUM; GOLD NANOPARTICLE; HERMES ANTIGEN; HYALURONAN MEDIATED MOTILITY RECEPTOR; HYALURONAN RECEPTOR; HYALURONIC ACID; HYDROGEN PEROXIDE; MITOMYCIN; PACLITAXEL; PROTEIN HAS 2; PROTEIN SPAM 1; QUANTUM DOT; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GROWTH; CARBOHYDRATE ANALYSIS; CARBOHYDRATE METABOLISM; CARBOHYDRATE SYNTHESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; IMAGE ANALYSIS; INNATE IMMUNITY; MESENCHYME CELL; NANOPROBE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIZATION; REVIEW; TISSUE INJURY; TISSUE REPAIR;

ANIMALS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYALURONIC ACID; MOLECULAR IMAGING;

EID: 79953753019     PISSN: 17579694     EISSN: 17579708     Source Type: Journal    
DOI: 10.1039/c0ib00096e     Document Type: Review

References (144)

1. (a) J. M. Lee, S. Dedhar, R. Kalluri and E. W. Thompson, The epithelial-mesenchymal transition: new insights in signaling, development, and disease, J. Cell Biol., 2006, 172(7), 973-81;
2. (b) M. J. Paszek and V. M. Weaver, The tension mounts: mechanics meets morphogenesis and malignancy, J. Mammary Gland Biol. Neoplasia, 2004, 9(4), 325-42;
3. (c) R. Xu, A. Boudreau and M. J. Bissell, Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices, Cancer Metastasis Rev., 2009, 28(1-2), 167-76;
4. (d) D. E. Ingber, Can cancer be reversed by engineering the tumor microenvironment?, Semin. Cancer Biol., 2008, 18(5), 356-64;
5. (e) C. Box, S. J. Rogers, M. Mendiola and S. A. Eccles, Tumour-microenvironmental interactions: paths to progression and targets for treatment, Semin. Cancer Biol., 2010, 20(3), 128-38.
6. M. D. Sternlicht, M. J. Bissell and Z. Werb, The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter, Oncogene, 2000, 19(8), 1102-13. (Pubitemid 30153797)
7. (a) C. A. Maxwell, E. Rasmussen, F. Zhan, J. J. Keats, S. Adamia, E. Strachan, M. Crainie, R. Walker, A. R. Belch, L. M. Pilarski, B. Barlogie, J. Shaughnessy, Jr and T. Reiman, RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma, Blood, 2004, 104(4), 1151-8;
8. (b) P. A. Kenny and M. J. Bissell, Tumor reversion: correction of malignant behavior by microenvironmental cues, Int. J. Cancer, 2003, 107(5), 688-95;
9. (c) Y. Li, L. Li, T. J. Brown and P. Heldin, Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells, Int. J. Cancer, 2007, 120(12), 2557-67;
10. (d) B. P. Toole, Hyaluronan: from extracellular glue to pericellular cue, Nat. Rev. Cancer, 2004, 4(7), 528-39.
11. (a) F. Wang, R. K. Hansen, D. Radisky, T. Yoneda, M. H. Barcellos-Hoff, O. W. Petersen, E. A. Turley and M. J. Bissell, Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts, J. Natl. Cancer Inst., 2002, 94(19), 1494-503;
12. (b) V. M. Weaver, O. W. Petersen, F. Wang, C. A. Larabell, P. Briand, C. Damsky and M. J. Bissell, Reversion of the malignant phenotype of human breast cells in three-dimensional culture and n vivo by integrin blocking antibodies, J. Cell Biol., 1997, 137(1), 231-45;
13. (c) C. L. Hall, B. Yang, X. Yang, S. Zhang, M. Turley, S. Samuel, L. A. Lange, C. Wang, G. D. Curpen, R. C. Savani, A. H. Greenberg and E. A. Turley, Overexpression of the hyaluronan receptorRHAMMis transforming and is also required for H-ras transformation, Cell, 1995, 82(1), 19-26.
14. (a) J. Condeelis and J. W. Pollard, Macrophages: obligate partners for tumor cell migration, invasion, and metastasis, Cell, 2006, 124(2), 263-6;
15. (b) L. M. Postovit, N. V. Margaryan, E. A. Seftor and M. J. Hendrix, Role of nodal signaling and the microenvironment underlying melanoma plasticity, Pigm. Cell Melanoma Res., 2008, 21(3), 348-57;
16. (c) M. J. Bissell, D. C. Radisky, A. Rizki, V. M. Weaver and O. W. Petersen, The organizing principle: microenvironmental influences n the normal and malignant breast, Differentiation, 2002, 70(9-10), 537-46;
17. (d) E. A. Turley, M. Veiseh, D. C. Radisky and M. J. Bissell, Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression?, Nat. Clin. Pract. Oncol., 2008, 5(5), 280-90;
18. (e) M. Egeblad, E. S. Nakasone and Z. Werb, Tumors as organs: complex tissues that interface with the entire organism, Dev. Cell, 2010, 18(6), 884-901;
19. (f) L. Vera-Ramirez, P. Sanchez-Rovira, C. L. Ramirez-Tortosa, J. L. Quiles, M. C. Ramirez-Tortosa, J. C. Alvarez, M. Fernandez-Navarro and J. A. Lorente, Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach, Cancer Treat. Rev., 2010, 36(6), 477-84.
20. (a) A. H. Beck, I. Espinosa, C. B. Gilks, M. van de Rijn and R. B. West, The fibromatosis signature defines a robust stromal response in breast carcinoma, Lab. Invest., 2008, 88(6), 591-601;
21. (b) K. C. Flanders and L. M. Wakefield, Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression, J. Mammary Gland Biol. Neoplasia, 2009, 14(2), 131-44;
22. (c) T. S. Pandit, W. Kennette, L. Mackenzie, G. Zhang, W. Al-Katib, J. Andrews, S. A. Vantyghem, D. G. Ormond, A. L. Allan, D. I. Rodenhiser, A. F. Chambers and A. B. Tuck, Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment, Int. J. Oncol., 2009, 35(2), 297-308;
23. (d) J. O'Brien and P. Schedin, Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer?, J. Mammary Gland Biol. Neoplasia, 2009, 14(2), 145-57;
24. (e) C. R. Acharya, D. S. Hsu, C. K. Anders, A. Anguiano, K. H. Salter, K. S. Walters, R. C. Redman, S. A. Tuchman, C. A. Moylan, S. Mukherjee, W. T. Barry, H. K. Dressman, G. S. Ginsburg, K. P. Marcom, K. S. Garman, G. H. Lyman, J. R. Nevins and A. Potti, Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer, JAMA, J. Am.Med. Assoc., 2008, 299(13), 1574-87;
25. (f) H. F. Dvorak, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing, N. Engl. J. Med., 1986, 315(26), 1650-9;
26. (g) C. Derleth and I. A. Mayer, Antiangiogenic therapies in early-stage breast cancer, Clin. Breast Cancer, 2010, 10(Suppl 1), E23-31.
27. (a) P. Schedin, J. O'Brien, M. Rudolph, T. Stein and V. Borges, Microenvironment of the involuting mammary gland mediates mammary cancer progression, J. Mammary Gland Biol. Neoplasia, 2007, 12(1), 71-82;
28. (b) E. A. McSherry, S. Donatello, A. M. Hopkins and S. McDonnell, Molecular basis of invasion in breast cancer, Cell. Mol. Life Sci., 2007, 64(24), 3201-18.
29. (a) L. M. Coussens and Z. Werb, Inflammatory cells and cancer: think different!, J. Exp. Med., 2001, 193(6), F23-6;
30. (b) J. A. Van Ginderachter, S. Meerschaut, Y. Liu, L. Brys, K. De. Groeve, G. Hassanzadeh Ghassabeh, G. Raes and P. De Baetselier, Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer, Blood, 2006, 108(2), 525-35.
31. M. H. Barcellos-Hoff and R. J. Akhurst, Transforming growth factor-beta in breast cancer: too much, too late, Breast Cancer Res., 2009, 11(1), 202.
32. T. Stein, N. Salomonis, D. S. Nuyten, M. J. van de Vijver and B. A. Gusterson, A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasis, J. Mammary Gland Biol. Neoplasia, 2009, 14(2), 99-116.
33. (a) J. Y. Hsu and H. A. Wakelee, Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy, BioDrugs, 2009, 23(5), 289-304;
34. (b) E. A. Perez, A. Moreno-Aspitia, E. Aubrey Thompson and C. A. Andorfer, Adjuvant therapy of triple negative breast cancer, Breast Cancer Res. Treat., 2010, 120(2), 285-91.
35. (a) R. H. Tammi, A. Kultti, V. M. Kosma, R. Pirinen, P. Auvinen and M. I. Tammi, Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan, Semin. Cancer Biol., 2008, 18(4), 288-95;
36. (b) A. D. Theocharis, S. S. Skandalis, G. N. Tzanakakis and N. K. Karamanos, Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting, FEBS J., 2010, 277(19), 3904-23;
37. (c) L. Alaniz, M. Garcia, M. Rizzo, F. Piccioni and G. Mazzolini, Altered hyaluronan biosynthesis and cancer progression: an immunological perspective, Mini-Rev. Med. Chem., 2009, 9(13), 1538-46;
38. (d) I. O. Potapenko, V. D. Haakensen, T. Luders, A. Helland, I. Bukholm, T. Sorlie, V. N. Kristensen, O. C. Lingjaerde and A. L. Borresen-Dale, Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression, Mol. Oncol., 2010, 4(2), 98-118.
39. M. Veiseh, J. Zhang, R. C. Savani, R. E. Harrison, D. Mikilus, L. Collis, J. Koropatnick, L. Luyt, M. J. Bissell and E. A. Turley, Imaging the Remodeling Microenvironment of Injured and Neoplastic Tissues with Hyaluronan-Based Functional Probes, in review, 2011.
40. P. H. Weigel and J. H. Yik, Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors, Biochim. Biophys. Acta, Gen. Subj., 2002, 1572(2-3), 341-63.
41. (a) R. C. Savani and E. A. Turley, The role of hyaluronan and its receptors in restenosis after balloon angioplasty: development of a potential therapy, Int. J. Tissue React., 1995, 17(4), 141-51;
42. (b) P. W. Noble and D. Jiang, Matrix regulation of lung injury, inflammation, and repair: the role of innate immunity, Proc. Am. Thorac. Soc., 2006, 3(5), 401-4.
43. (a) S. R. Hamilton, S. F. Fard, F. F. Paiwand, C. Tolg, M. Veiseh, C. Wang, J. B. McCarthy, M. J. Bissell, J. Koropatnick and E. A. Turley, The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells, J. Biol. Chem., 2007, 282(22), 16667-80;
44. (b) L. P. Wang, X. M. Xu, H. Y. Ning, S. M. Yang, J. G. Chen, J. Y. Yu, H. Y. Ding, C. B. Underhill and L. R. Zhang, Expression of PH20 in primary and metastatic breast cancer and its pathological significance, Zhonghua Bing Li Xue Za Zhi, 2004, 33(4), 320-3.
45. (a) R. D. Price, M. G. Berry and H. A. Navsaria, Hyaluronic acid: the scientific and clinical evidence, J. Plast., Reconstr. Aesthetic Surg., 2007, 60(10), 1110-9;
46. (b) W. Y. Chen and G. Abatangelo, Functions of hyaluronan in wound repair, Wound Repair Regener., 1999, 7(2), 79-89;
47. (c) K. R. Taylor and R. L. Gallo, Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation, FASEB J., 2006, 20(1), 9-22;
48. (d) D. Jiang, J. Liang and P. W. Noble, Hyaluronan in tissue injury and repair, Annu. Rev. Cell Dev. Biol., 2007, 23, 435-61;
49. (e) M. Slevin, J. Krupinski, J. Gaffney, S. Matou, D. West, H. Delisser, R. C. Savani and S. Kumar, Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways, Matrix Biol., 2007, 26(1), 58-68;
50. (f) M. I. Tammi, A. J. Day and E. A. Turley, Hyaluronan and homeostasis: a balancing act, J. Biol. Chem., 2002, 277(7), 4581-4. (Pubitemid 34968482)
51. B. P. Toole and M. G. Slomiany, Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells, Semin. Cancer Biol., 2008, 18(4), 244-50.
52. (a) R. Stern, Hyaluronidases in cancer biology, Semin. Cancer Biol., 2008, 18(4), 275-80;
53. (b) N. Itano, Simple primary structure, complex turnover regulation and multiple roles of hyaluronan, J. Biochem., 2008, 144(2), 131-7;
54. (c) J. Gaffney, S. Matou-Nasri, M. Grau-Olivares and M. Slevin, Therapeutic applications of hyaluronan, Mol. BioSyst., 2010, 6(3), 437-43;
55. (d) K. S. Girish and K. Kemparaju, The magic glue hyaluronan and its eraser hyaluronidase: a biological overview, Life Sci., 2007, 80(21), 1921-43. (Pubitemid 46601516)
56. D. G. Jackson, Immunological functions of hyaluronan and its receptors in the lymphatics, Immunol. Rev., 2009, 230(1), 216-31.
57. (a) J. A. Sloane, D. Blitz, Z. Margolin and T. Vartanian, A clear and present danger: endogenous ligands of Toll-like receptors, NeuroMol. Med., 2010, 12(2), 149-63;
58. (b) E. P. Buchanan, M. T. Longaker and H. P. Lorenz, Fetal skin wound healing, Adv. Clin. Chem., 2009, 48, 137-61.
59. (a) M. E. Monzon, N. Fregien, N. Schmid, N. S. Falcon, M. Campos, S. M. Casalino-Matsuda and R. M. Forteza, Reactive oxygen species and hyaluronidase 2 regulate airway epithelial hyaluronan fragmentation, J. Biol. Chem., 2010, 285(34), 26126-34;
60. (b) V. B. Lokeshwar, P. Gomez, M. Kramer, J. Knapp, M. A. McCornack, L. E. Lopez, N. Fregien, N. Dhir, S. Scherer, D. J. Klumpp, M. Manoharan, M. S. Soloway and B. L. Lokeshwar, Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter, J. Biol. Chem., 2008, 283(43), 29215-27.
61. (a) B. P. Toole and M. G. Slomiany, Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance, Drug Resist. Updates, 2008, 11(3), 110-21;
62. (b) E. A. Turley, P. W. Noble and L. Y. Bourguignon, Signaling properties of hyaluronan receptors, J. Biol. Chem., 2002, 277(7), 4589-92. (Pubitemid 34968484)
63. R. Stern, A. A. Asari and K. N. Sugahara, Hyaluronan fragments: an information-rich system, Eur. J. Cell Biol., 2006, 85(8), 699-715. (Pubitemid 44070579)
64. R. Stern and H. I. Maibach, Hyaluronan in skin: aspects of aging and its pharmacologic modulation, Clin. Dermatol., 2008, 26(2), 106-22. (Pubitemid 351620989)
65. P. H. Weigel and P. L. DeAngelis, Hyaluronan synthases: a decade-plus of novel glycosyltransferases, J. Biol. Chem., 2007, 282(51), 36777-81.
66. L. Cuthbertson, I. L. Mainprize, J. H. Naismith and C. Whitfield, Pivotal roles of the outer membrane polysaccharide export and polysaccharide copolymerase protein families in export of extracellular polysaccharides in gram-negative bacteria, Microbiol. Mol. Biol. Rev., 2009, 73(1), 155-77.
67. (a) M. A. Simpson and V. B. Lokeshwar, Hyaluronan and hyaluronidase in genitourinary tumors, Front. Biosci., 2008, 13, 5664-80;
68. (b) K. M. Bullard, H. R. Kim, M. A. Wheeler, C. M. Wilson, C. L. Neudauer, M. A. Simpson and J. B. McCarthy, Hyaluronan synthase-3 is upregulated in metastatic colon carcinoma cells and manipulation of expression alters matrix retention and cellular growth, Int. J. Cancer, 2003, 107(5), 739-46. (Pubitemid 37339727)
69. L. Udabage, G. R. Brownlee, S. K. Nilsson and T. J. Brown, The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer, Exp. Cell Res., 2005, 310(1), 205-17. (Pubitemid 41393701)
70. M. A. Simpson, C. M. Wilson and J. B. McCarthy, Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice, Am. J. Pathol., 2002, 161(3), 849-57. (Pubitemid 34988372)
71. (a) M. Eberlein, K. A. Scheibner, K. E. Black, S. L. Collins, Y. Chan-Li, J. D. Powell and M. R. Horton, Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression, J. Inflammation, 2008, 5, 20;
72. (b) L. Soltes, R. Mendichi, G. Kogan, J. Schiller, M. Stankovska and J. Arnhold, Degradative action of reactive oxygen species on hyaluronan, Biomacromolecules, 2006, 7(3), 659-68;
73. (c) G. Mendoza, A. I. Alvarez, M. M. Pulido, A. J. Molina, G. Merino, R. Real, P. Fernandes and J. G. Prieto, Inhibitory effects of different antioxidants on hyaluronan depolymerization, Carbohydr. Res., 2007, 342(1), 96-102;
74. (d) R. Moseley, M. Walker, R. J. Waddington and W. Y. Chen, Comparison of the antioxidant properties of wound dressing materials - carboxymethylcellulose, hyaluronan benzyl ester and hyaluronan, towards polymorphonuclear leukocyte-derived reactive oxygen species, Biomaterials, 2003, 24(9), 1549-57;
75. (e) G. M. Campo, A. Avenoso, S. Campo, A. Ferlazzo, D. Altavilla, C. Micali and A. Calatroni, Aromatic trap analysis of free radicals production in experimental collagen-induced arthritis in the rat: protective effect of glycosaminoglycans treatment, Free Radical Res., 2003, 37(3), 257-68. (Pubitemid 36181882)
76. (a) L. Y. Bourguignon, P. A. Singleton, F. Diedrich, R. Stern and E. Gilad, CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion, J. Biol. Chem., 2004, 279(26), 26991-7007;
77. (b) M. C. Gasingirwa, J. Thirion, J. Mertens-Strijthagen, S. Wattiaux-De Coninck, B. Flamion, R. Wattiaux and M. Jadot, Endocytosis of hyaluronidase-1 by the liver, Biochem. J., 2010, 430(2), 305-13.
78. C. A. Maxwell, J. McCarthy and E. Turley, Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?, J. Cell Sci., 2008, 121(7), 925-32. (Pubitemid 351639411)
79. C. Tolg, S. R. Hamilton, K. A. Nakrieko, F. Kooshesh, P. Walton, J. B. McCarthy, M. J. Bissell and E. A. Turley, Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair, J. Cell Biol., 2006, 175(6), 1017-28.
80. (a) J. I. Lopez, T. D. Camenisch, M. V. Stevens, B. J. Sands, J. McDonald and J. A. Schroeder, CD44 attenuates metastatic invasion during breast cancer progression, Cancer Res., 2005, 65(15), 6755-63;
81. (b) C. Tolg, R. Poon, R. Fodde, E. A. Turley and B. A. Alman, Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor), Oncogene, 2003, 22(44), 6873-82.
82. V. B. Lokeshwar and M. G. Selzer, Hyalurondiase: both a tumor promoter and suppressor, Semin. Cancer Biol., 2008, 18(4), 281-7.
83. P. K. Auvinen, J. J. Parkkinen, R. T. Johansson, U. M. Agren, R. H. Tammi, M. J. Eskelinen and V. M. Kosma, Expression of hyaluronan in benign and malignant breast lesions, Int. J. Cancer, 1997, 74(5), 477-81.
84. (a) P. Auvinen, R. Tammi, J. Parkkinen, M. Tammi, U. Agren, R. Johansson, P. Hirvikoski, M. Eskelinen and V. M. Kosma, Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival, Am. J. Pathol., 2000, 156(2), 529-36;
85. (b) S. Suwiwat, C. Ricciardelli, R. Tammi, M. Tammi, P. Auvinen, V. M. Kosma, R. G. LeBaron, W. A. Raymond, W. D. Tilley and D. J. Horsfall, Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer, Clin. Cancer Res., 2004, 10(7), 2491-8.
86. (a) P. Casalini, M. L. Carcangiu, R. Tammi, P. Auvinen, V. M. Kosma, P. Valagussa, M. Greco, A. Balsari, S. Menard and E. Tagliabue, Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact, Clin. Cancer Res., 2008, 14(1), 25-31;
87. (b) Z. Palyi-Krekk, M. Barok, J. Isola, M. Tammi, J. Szollosi and P. Nagy, Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer, Eur. J. Cancer, 2007, 43(16), 2423-33. (Pubitemid 47625976)
88. K. Unger, J. Wienberg, A. Riches, L. Hieber, A. Walch, A. Brown, P. C. O'Brien, C. Briscoe, L. Gray, E. Rodriguez, G. Jackl, J. Knijnenburg, G. Tallini, M. Ferguson-Smith and H. Zitzelsberger, Novel gene rearrangements in transformed breast cells identified by high-resolution breakpoint analysis of chromosomal aberrations, Endocr. Relat. Cancer, 2010, 17(1), 87-98.
89. (a) L. R. Oliveira, S. S. Jeffrey and A. Ribeiro-Silva, Stem cells in human breast cancer, Histol. Histopathol., 2010, 25(3), 371-85;
90. (b) A. L. Stratford, K. Reipas, C. Maxwell and S. E. Dunn, Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer, Expert Rev. Mol. Med., 2010, 12, e22;
91. (c) K. Kai, Y. Arima, T. Kamiya and H. Saya, Breast cancer stem cells, Breast Cancer, 2010, 17(2), 80-5;
92. (d) S. Chuthapisith, J. Eremin, M. El-Sheemey and O. Eremin, Breast cancer chemoresistance: emerging importance of cancer stem cells, Surg. Oncol., 2010, 19(1), 27-32.
93. (a) W. Xie, Y. Huang, A. Guo and W. Wu, Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cells, PLoS One, 2010, 5(5), e10850;
94. (b) W. Xie, Y. Wang, Y. Huang, H. Yang, J. Wang and Z. Hu, Toll-like receptor 2 mediates invasion via activating NF-kappaB inMDA-MB-231 breast cancer cells, Biochem. Biophys. Res. Commun., 2009, 379(4), 1027-32;
95. (c) S. A. Armogida, N. M. Yannaras, A. L. Melton and M. D. Srivastava, Identification and quantification of innate immune system mediators in human breast milk, Allergy Asthma Proc., 2004, 25(5), 297-304.
96. B. Dave and J. Chang, Treatment resistance in stem cells and breast cancer, J. Mammary Gland Biol. Neoplasia, 2009, 14(1), 79-82.
97. (a) P. A. Martin-DeLeon, Epididymal SPAM1 and its impact on sperm function, Mol. Cell. Endocrinol., 2006, 250(1-2), 114-21;
98. (b) A. B. Csoka, G. I. Frost and R. Stern, The six hyaluronidaselike genes in the human and mouse genomes, Matrix Biol., 2001, 20(8), 499-508. (Pubitemid 33109098)
99. D. J. Beech, A. K. Madan and N. Deng, Expression of PH-20 in normal and neoplastic breast tissue, J. Surg. Res., 2002, 103(2), 203-7. (Pubitemid 34948502)
100. (a) F. Gao, Y. Liu, Y. He, C. Yang, Y. Wang, X. Shi and G. Wei, Hyaluronan oligosaccharides promote excisional wound healing through enhanced angiogenesis, Matrix Biol., 2010, 29(2), 107-16;
101. (b) F. Gao, P. Okunieff, Z. Han, I. Ding, L. Wang, W. Liu, J. Zhang, S. Yang, J. Chen, C. B. Underhill, S. Kim and L. Zhang, Hypoxia-induced alterations in hyaluronan and hyaluronidase, Adv. Exp. Med. Biol., 2005, 566, 249-56. (Pubitemid 43779509)
102. C. Tolg, S. Hamilton, L. Morningstar, J. Zhang, K. Esguerra, P. Telmer, L. Luyt, R. Harrison, J. McCarthy and E. Turley, Rhamm promotes interphase microtubule instability and mitotic spindle integrity through Mek1/Erk1/2 activity, J. Biol. Chem., 2010, 285(34), 26461-74.
103. H. Koyama, N. Kobayashi, M. Harada, M. Takeoka, Y. Kawai, K. Sano, M. Fujimori, J. Amano, T. Ohhashi, R. Kannagi, K. Kimata, S. Taniguchi and N. Itano, Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment, Am. J. Pathol., 2008, 172(1), 179-93. (Pubitemid 351186379)
104. (a) M. Veiseh, E. A. Turley and M. J. Bissell, A top-down Analysis of a Dynamic Environment: Extracellular Matrix Structure and Function, in Nanotechnology and Tissue Engineering: The Scaffold, ed. C. T. Laurencin and L. S. Nair, CRS Press/Taylor and Francis Group FL, 2008, pp. 6387-6392;
105. (b) D. D. Allison and K. J. Grande-Allen, Review. Hyaluronan: a powerful tissue engineering tool, Tissue Eng., 2006, 12(8), 2131-40.
106. I. De Stefano, A. Battaglia, G. F. Zannoni, M. G. Prisco, A. Fattorossi, D. Travaglia, S. Baroni, D. Renier, G. Scambia, C. Ferlini and D. Gallo, Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts, Cancer Chemother. Pharmacol., 2010.
107. (a) Y. Matsumura and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 1986, 46(12 Pt 1), 6387-92;
108. (b) H. Maeda, J. Wu, T. Sawa, Y. Matsumura and K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Controlled Release, 2000, 65(1-2), 271-84. (Pubitemid 30122932)
109. S. R. Hamilton, M. Veiseh, C. Tolg, R. Tirona, J. Richardson, R. Brown, M. Gonzalez, M. Vanzieleghem, P. Anderson, S. Asculai, F. Winnik, R. Savani, D. Freeman, L. Luyt, J. Koropatnick and E. A. Turley, Pharmacokinetics and Pharmacodynamics of hyaluronan infused into healthy human volunters, The Open Drug Metabolism Journal, 2009, 3, 43-55.
110. H. Lee, K. Lee, I. K. Kim and T. G. Park, Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes, Biomaterials, 2008, 29(35), 4709-18.
111. (a) H. Lee, K. Lee and T. G. Park, Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity, Bioconjugate Chem., 2008, 19(6), 1319-25;
112. (b) E. J. Oh, K. Park, K. S. Kim, J. Kim, J. A. Yang, J. H. Kong, M. Y. Lee, A. S. Hoffman and S. K. Hahn, Target specific and longacting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives, J. Controlled Release, 2010, 141(1), 2-12.
113. (a) T. J. Brown, The development of hyaluronan as a drug transporter and excipient for chemotherapeutic drugs, Curr. Pharm. Biotechnol., 2008, 9(4), 253-60;
114. (b) V. M. Platt and F. C. Szoka Jr, Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor, Mol. Pharmaceutics, 2008, 5(4), 474-86.
115. Y. Luo, N. J. Bernshaw, Z. R. Lu, J. Kopecek and G. D. Prestwich, Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates, Pharm. Res., 2002, 19(4), 396-402. (Pubitemid 34408935)
116. D. Coradini, C. Pellizzaro, G. Miglierini, M. G. Daidone and A. Perbellini, Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line, Int. J. Cancer, 1999, 81(3), 411-6. (Pubitemid 29165200)
117. (a) Y. Luo and G. D. Prestwich, Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate, Bioconjugate Chem., 1999, 10(5), 755-63;
118. (b) Y. Luo, M. R. Ziebell and G. D. Prestwich, A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells, Biomacromolecules, 2000, 1(2), 208-18.
119. Y. Ogawa, K. Kubota, H. Ue, Y. Kataoka, M. Tadokoro, K. Miyatake, K. Tsuzuki, T. Yamanishi, S. Itoh, J. Hitomi, N. Hamada, S. Kariya, M. Fukumoto, A. Nishioka and T. Inomata, Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), Int. J. Oncol., 2009, 34(3), 609-18.
120. G. Pitarresi, E. F. Craparo, F. S. Palumbo, B. Carlisi and G. Giammona, Composite nanoparticles based on hyaluronic acid chemically cross-linked with alpha,beta-polyaspartylhydrazide, Biomacromolecules, 2007, 8(6), 1890-8. (Pubitemid 47009968)
121. H. Lee, H. Mok, S. Lee, Y. K. Oh and T. G. Park, Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels, J. Controlled Release, 2007, 119(2), 245-52.
122. (a) M. S. Cohen, S. Cai, Y. Xie and M. L. Forrest, A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo, Am. J. Surg., 2009, 198(6), 781-6;
123. (b) Y. I. Jeong, S. T. Kim, S. G. Jin, H. H. Ryu, Y. H. Jin, T. Y. Jung, I. Y. Kim and S. Jung, Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation, J. Pharm. Sci., 2008, 97(3), 1268-76;
124. (c) B. Rosenberg, Platinum Complexes for Treatment of Cancer, Interdisciplinary Science Reviews, 1978, 3(2), 134-147.
125. A. K. Yadav, P. Mishra, S. Jain, A. K. Mishra and G. P. Agrawal, Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin, J. Drug Targeting, 2008, 16(6), 464-78.
126. H. Lee, C. H. Ahn and T. G. Park, Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin, Macromol. Biosci., 2009, 9(4), 336-42.
127. D. Peer and R. Margalit, Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models, Neoplasia, 2004, 6(4), 343-53.
128. D. Peer and R. Margalit, Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models, Int. J. Cancer, 2004, 108(5), 780-9.
129. H. Lee, K. Lee, I. K. Kim and T. G. Park, Fluorescent gold nanoprobe sensitive to intracellular reactive oxygen species, Adv. Funct. Mater., 2009, 19(12), 1884-1890.
130. Y. Lee, H. Lee, Y. B. Kim, J. Kim, T. Hyeon, H. Park, P. B. Messersmith and T. G. Park, Bioinspired surface immobilization of hyaluronic acid on monodisperse magnetite nanocrystals for targeted cancer imaging, Adv. Mater. Deerfield, 2008, 20(21), 4154-4157.
131. L. Shiftan, T. Israely, M. Cohen, V. Frydman, H. Dafni, R. Stern and M. Neeman, Magnetic resonance imaging visualization of hyaluronidase in ovarian carcinoma, Cancer Res., 2005, 65(22), 10316-23.
132. J. Kim, K. S. Kim, G. Jiang, H. Kang, S. Kim, B. S. Kim, M. H. Park and S. K. Hahn, In vivo real-time bioimaging of hyaluronic acid derivatives using quantum dots, Biopolymers, 2008, 89(12), 1144-53.
133. K. S. Kim, W. Hur, S. J. Park, S.W. Hong, J. E. Choi, E. J. Goh, S. K. Yoon and S. K. Hahn, Bioimaging for targeted delivery of hyaluronic acid derivatives to the livers in cirrhotic mice using quantum dots, ACS Nano, 2010, 4(6), 3005-14.
134. S. H. Bhang, N. Won, T. J. Lee, H. Jin, J. Nam, J. Park, H. Chung, H. S. Park, Y. E. Sung, S. K. Hahn, B. S. Kim and S. Kim, Hyaluronic acid-quantum dot conjugates for in vivo lymphatic vessel imaging, ACS Nano, 2009, 3(6), 1389-98.
135. E. N. Harris, S. V. Kyosseva, J. A. Weigel and P. H. Weigel, Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE), J. Biol. Chem., 2007, 282(5), 2785-97.
136. S. Gustafson, The influence of sulfated polysaccharides on the circulating levels of hyaluronan, Glycobiology, 1997, 7(8), 1209-14.
137. (a) B. Zhou, J. A. Weigel, L. Fauss and P. H. Weigel, Identification of the hyaluronan receptor for endocytosis (HARE), J. Biol. Chem., 2000, 275(48), 37733-41;
138. (b) S. Sugahara, S. Okuno, T. Yano, H. Hamana and K. Inoue, Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting, Biol. Pharm. Bull., 2001, 24(5), 535-43;
139. (c) K. Y. Choi, H. Chung, K. H. Min, H. Y. Yoon, K. Kim, J. H. Park, I. C. Kwon and S. Y. Jeong, Self-assembled hyaluronic acid nanoparticles for active tumor targeting, Biomaterials, 2010, 31(1), 106-14;
140. (d) V. Orian-Rousseau, CD44, a therapeutic target for metastasising tumours, Eur. J. Cancer, 2010, 46(7), 1271-7.
141. J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner and L. Bullinger, Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches, Blood, 2006, 108(13), 4109-17.
142. C. A. Maxwell, J. J. Keats, A. R. Belch, L. M. Pilarski and T. Reiman, Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity, Cancer Res., 2005, 65(3), 850-60.
143. (a) K. Giannopoulos, A. Dmoszynska, M. Kowal, J. Rolinski, E. Gostick, D. A. Price, J. Greiner, M. Rojewski, S. Stilgenbauer, H. Dohner and M. Schmitt, Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia, Leukemia, 2010, 24(4), 798-805;
144. (b) M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, D. E. Speiser, S. Gnjatic, P. Guillaume, M. Ringhoffer, R. F. Schlenk, P. Liebisch, D. Bunjes, H. Shiku, H. Dohner and J. Greiner, RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses, Blood, 2008, 111(3), 1357-65.